SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2020
Commission File Number: 001- 39167
Molecular Data Inc.
5/F, Building 12, 1001 North Qinzhou Road
Xuhui District, Shanghai 201109
People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Change to Audit Committee Composition
Molecular Data Inc. (“Molecular Data” or the “Company”) (Nasdaq: MKD), a leading technology-driven platform in China’s chemical industry, today announced that Dr. Dongliang Chang ceases to serve as a member of the audit committee of the board of directors of the Company, effective immediately to ensure audit committee independence. Dr. Chang will continue to serve as the Chairman of Board of Directors.
The Company will now have an audit committee of two members, Dr. Dawei Ma and Dr. Ning Zhu, who are independent directors, to comply with Rule 10A-3 under the Securities Exchange Act of 1934. The Company chose to follow its home country practice in lieu of the requirement under Nasdaq rule 5606(c) to have an audit committee of at least three members.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Molecular Data Inc.|
|By||:||/s/ Steven Foo|
|Title||:||Chief Financial Officer|
Date: December 29, 2020